Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis

References

• SospedraMMartinRImmunology of multiple sclerosisAnnu Rev Immunol20052368374715771584
   PubMed Web of Science ®Google Scholar
• TullmanMJOverview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosisAm J Manag Care2013192 SupplS15S2023544716
   PubMed Web of Science ®Google Scholar
• FrischerJMBramowSDal-BiancoAThe relation between inflammation and neurodegeneration in multiple sclerosis brainsBrain2009132Pt 51175118919339255
   PubMed Web of Science ®Google Scholar
• JanardhanVBakshiRQuality of life in patients with multiple sclerosis: the impact of fatigue and depressionJ Neurol Sci20022051515812409184
   PubMed Web of Science ®Google Scholar
• ZiemssenTDerfussTde StefanoNOptimizing treatment success in multiple sclerosisJ Neurol201626361053106526705122
   PubMed Web of Science ®Google Scholar
• BanwellBGiovannoniGHawkesCLublinFEditors’ welcome and a working definition for a multiple sclerosis cureMult Scler Relat Disord201322656725877624
   PubMed Web of Science ®Google Scholar
• GarrisonLPJrNeumannPJEricksonPMarshallDMullinsCDUsing real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force reportValue Health200710532633517888097
   PubMed Web of Science ®Google Scholar
• TrojanoMTintoreMMontalbanXTreatment decisions in multiple sclerosis: insights from real-world observational studiesNat Rev Neurol201713210511828084327
   PubMed Web of Science ®Google Scholar
• SonderJMBalkLJvan der LindenFABosmaLVPolmanCHUitdehaagBMToward the use of proxy reports for estimating long-term patient-reported outcomes in multiple sclerosisMult Scler201521141865187125257617
   PubMed Web of Science ®Google Scholar
• KobeltGThompsonABergJGannedahlMErikssonJNew insights into the burden and costs of multiple sclerosis in EuropeMult Scler20172381123113628273775
   PubMed Web of Science ®Google Scholar
• QizilbashNMendezISanchez-de la RosaRBenefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosisClin Ther2012341159176.e522284996
   PubMed Web of Science ®Google Scholar
• OliverBJKohliEKasperLHInterferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trialsJ Neurol Sci20113021–29610521167504
   PubMed Web of Science ®Google Scholar
• BrandesDWCallenderTLathiEO’LearySA review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse eventsCurr Med Res Opin2009251779219210141
   PubMed Web of Science ®Google Scholar
• MenzinJCaonCNicholsCWhiteLAFriedmanMPillMWNarrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosisJ Manag Care Pharm2013191 Suppl AS24S4023383731
   PubMed Web of Science ®Google Scholar
• TreadawayKCutterGSalterAFactors that influence adherence with disease-modifying therapy in MSJ Neurol2009256456857619444532
   PubMed Web of Science ®Google Scholar
• HofmannMBrinkmannVZerwesHGFTY720 preferentially depletes naive T cells from peripheral and lymphoid organsInt Immunopharmacol2006613–141902191017161343
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362540241520089954
   PubMed Web of Science ®Google Scholar
• CalabresiPARadueEWGoodinDSafety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialLancet Neurol201413654555624685276
   PubMed Web of Science ®Google Scholar
• MontalbanXComiGAntelJLong-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosisJ Neurol2015262122627263426338810
   PubMed Web of Science ®Google Scholar
• KapposLO’ConnorPRadueEWLong-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trialNeurology201584151582159125795646
   PubMed Web of Science ®Google Scholar
• CohenJAKhatriBBarkhofFLong-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS studyJ Neurol Neurosurg Psychiatry201687546847526111826
   PubMed Web of Science ®Google Scholar
• HohlfeldRKapposLTomicDEarly fingolimod treatment improves disease outcomes at 2 and 4 years in patients with relapsing-remitting multiple sclerosisNeurology20178816 Suppl6332
   Google Scholar
• CohenJTenenbaumNBhattAPimentelRKapposLRadiological evidence of the long-term effect of fingolimod treatment in patients with relapsing-remitting multiple sclerosisNeurology20178816 Suppl4409
   Google Scholar
• CohenJHartungHKhatriBEarly switch to fingolimod for achieving no evidence of multiple sclerosis disease activity: 8-year analysis of data from the TRANSFORMS studyNeurology20178816 Suppl4390
   Google Scholar
• ZiemssenTMedinJCoutoCAMitchellCRMultiple sclerosis in the real world: a systematic review of fingolimod as a case studyAutoimmun Rev201716435537628212923
   PubMed Web of Science ®Google Scholar
• ZiemssenTKernRCornelissenCThe PANGAEA study design: a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practiceBMC Neurol2015159326084334
   PubMed Web of Science ®Google Scholar
• ZiemssenTAlbrechtHHaasJ5 Years effectiveness of fingolimod in daily clinical practice: results of the non-interventional study PANGAEA documenting RRMS patients treated with fingolimod in GermanyNeurology20178816 Suppl6345
   Google Scholar
• IzquierdoGDamasFParamoMDRuiz-PenaJLNavarroGThe real-world effectiveness and safety of fingolimod in relapsing- remitting multiple sclerosis patients: an observational studyPLoS One2017124e017617428453541
   PubMed Web of Science ®Google Scholar
• KapposLCohenJCollinsWFingolimod in relapsing multiple sclerosis: an integrated analysis of safety findingsMult Scler Relat Disord20143449450425877062
   PubMed Web of Science ®Google Scholar
• CohenJTenenbaumSBhatRPimentelRKapposLLong-term efficacy and safety of fingolimod in patients with RRMS: 10-year experience from LONGTERMS studyMult Scler J2017233 SupplP1879
   Google Scholar
• ZiemssenTAlbrechtHHaasJ5 Years safety experience with fingolimod in real world: results from PANGAEA, a non-interventional study of RRMS patients treated in GermanyMult Scler J2017233 SupplP1192
   Google Scholar
• Lebrun-FrenayCPapeixCKobeltGLong-term efficacy, safety, tolerability and quality of life with fingolimod treatment in patients with multiple sclerosis in real-world settings in France: VIRGILE two-year resultsMult Scler J2017233 SupplEP1716
   Google Scholar
• KillesteinJVennegoorAvan GoldeAEBourezRLWijlensMLWattjesMPPML-IRIS during fingolimod diagnosed after natalizumab discontinuationCase Rep Neurol Med2014201430787225506447
   PubMedGoogle Scholar
• AchtnichtsLObrejaOConenAFuxCANedeltchevKCryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimodJAMA Neurol201572101203120526457631
   PubMed Web of Science ®Google Scholar
• ForrestelAKModiBGLongworthSWilckMBMichelettiRGPrimary cutaneous Cryptococcus in a patient with multiple sclerosis treated with fingolimodJAMA Neurol201673335535626751160
   PubMed Web of Science ®Google Scholar
• SetoHNishimuraMMinamijiKDisseminated cryptococcosis in a 63-year-old patient with multiple sclerosis treated with fingolimodIntern Med201655223383338627853088
   PubMed Web of Science ®Google Scholar
• HagiyaHYoshidaHShimizuMHerpes zoster laryngitis in a patient treated with fingolimodJ Infect Chemother2016221283083227553068
   PubMed Web of Science ®Google Scholar
• PfenderNJelcicILinnebankMSchwarzUMartinRReactivation of herpesvirus under fingolimod: a case of severe herpes simplex encephalitisNeurology201584232377237825957334
   PubMed Web of Science ®Google Scholar
• IssaNPHentatiAVZV encephalitis that developed in an immunized patient during fingolimod therapyNeurology20158419910025416038
   PubMed Web of Science ®Google Scholar
• KawiorskiMMViedma-GuiardECosta-FrossardLCorralIPolydermatomal perineal and gluteal herpes zoster infection in a patient on fin-golimod treatmentEnferm Infecc Microbiol Clin201533213813924958672
   PubMed Web of Science ®Google Scholar
• ArvinAMWolinskyJSKapposLVaricella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for managementJAMA Neurol2015721313925419615
   PubMed Web of Science ®Google Scholar
• SubeiAMCohenJASphingosine 1-phosphate receptor modulators in multiple sclerosisCNS Drugs201529756557526239599
   PubMed Web of Science ®Google Scholar
• GoldRComiGPalaceJAssessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3B, open-label studyJ Neurol2014261226727624221641
   PubMed Web of Science ®Google Scholar
• LimmrothVHaverkampWDechendRFirst dose effects of fingolimod: final results of an in-depth ECG and Holter study in 6,998 German RRMS patientsMult Scler J2017233 SupplP764
   Google Scholar
• BermelRAHashmonayRMengXFingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitorsMult Scler Relat Disord20154327328026008945
   PubMed Web of Science ®Google Scholar
• YoshiiFMoriyaYOhnukiTRyoMTakahashiWNeurological safety of fingolimod: an updated reviewClin Exp Neuroimmunol20178323324328932291
   PubMedGoogle Scholar
• FoxEEdwardsKBurchGOutcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisMult Scler Relat Disord20143560761926265273
   PubMed Web of Science ®Google Scholar
• ZiemssenTAlbrechtHHaasJ5 Years effectiveness of fingolimod in daily clinical practice: results of the non-interventional study PANGAEAMult Scler J2017233 SupplP745
   Google Scholar
• AchironAArefHInshasiJEffectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle EastBMC Neurol201717115028784108
   PubMed Web of Science ®Google Scholar
• PapeixCLebrun-FrenayCLerayELong-term efficacy, safety, tolerability and quality of life with fingolimod treatment in patients with multiple sclerosis in real-world settings in France: VIRGILE one-year resultsMult Scler J2016223 SupplP1234
   Google Scholar
• KalincikTButzkuevenHObservational data: understanding the real MS worldMult Scler201622131642164827270498
   PubMed Web of Science ®Google Scholar
• FlacheneckerPBuckowKPugliattiMMultiple sclerosis registries in Europe: results of a systematic surveyMult Scler201420111523153224777278
   PubMed Web of Science ®Google Scholar
• Weinstock-GuttmanBMedinJKhanNAssessing no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis receiving fingolimod: results from a longitudinal, multicenter, real-world studyNeurology8816 Suppl4388
   Google Scholar
• ZiemssenTAlbrechtHHaasJ5 Years safety of fingolimod in real world: first results from PANGAEA, a non-interventional study of RRMS patients treated with fingolimod, on safety and adherence after 5 years of fingolimod in daily clinical practiceNeurology20178816 Suppl5365
   Google Scholar
• FragosoYDMultiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse eventsActa Neurol Belg2017117482182728528469
   PubMed Web of Science ®Google Scholar
• ZiemssenTKernRThomasKMultiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approachBMC Neurol20161612427484848
   PubMed Web of Science ®Google Scholar
• GiovannoniGTomicDBrightJRHavrdováE“No evident disease activity”: the use of combined assessments in the management of patients with multiple sclerosisMult Scler20172391179118728381105
   PubMed Web of Science ®Google Scholar
• van PeschVBELTRIMS: First results from a Belgian registry for treatments in Multiple SclerosisNewsletter of the Belgian Charcot Foundation2017425 Avaialble from: http://www.fondation-charcot.org/en/newsletters/35/ms-research-beltrims-registry-fund-charcot-belgianAccessed November 22, 2017.
   Google Scholar